Home / Production
Biological Pharmaceutical production technology is the key point of difference between BioPharm and botannical cannabis startups. We don’t grow any cannabis plants, we use patented organic chemistry methods and proprietary biosynthesis methods normally used in medicinal manufacture to produce chemically pure cannabinoids, economically at scale.
To date the medical cannabis market has been dominated by suppliers extracting cannabinoids from hemp. Farmers globally are switching food crops to hemp which is having significant impact on environment and global food supplies. Our plan allows us to produce nature identical cannabinoids using organic chemistry methods, or using a proprietary eco-friendly biological technology, and not requiring us to grow plants at all.
There are significant benefits to using our methods, including lower financial cost and environmental impact.
We aim to be the world’s largest supplier of generic pharmaceutical grade Cannabinoids (such as CBD, CBG, THCV etc). Using our patented organic chemistry, and cutting edge biological production methods we will produce generic, rare and novel cannabinoids more economically than can be done with traditional farming methods, with standardised purity and with less environmental impact.
Psilocybin mushrooms have been used by indigenous cultures for millennia for their therapeutic and mystical benefits. Western cultures have been denied this natural gift due to fear and taboo. Now, science has rediscovered its potential, and modern man is gaining access to this ancient tool.
Research is showing microdosing LSD (taking tiny amounts) to have powerful benefits, but the potential for overdose makes it unlikely to be allowed for public use. BioPharm have developed similar products with a ceiling level of effect to prevent overdose.
Ketamine is a popular surgical anaesthetic found to have mental health benefits, such as relief of treatment resistant depression, but is toxic to bladder. BioPharm team have worked on a number of improvements to this molecule.
MDMA is fast becoming a popular medicine for a variety of symptoms, but is toxic to heart and brain. BioPharm's EASE project has safer alternatives under development.
Stimulants such as cocaine and methamphetamine are widely used in the community but can have devastating consequences. Developing substitution drugs with less risk is becoming an attractive policy solution and we are working on the technology to get there.
Powered by WhatsApp Chat
